A Phase I Study of XJ101 in Chinese Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

March 26, 2024

Study Completion Date

September 1, 2024

Conditions

Staphylococcus Aureus Bloodstream Infection

Interventions

DRUG

XJ101 for Injection

XJ101 is a recombinant humanized single domain antibody-Fc (human immunoglobulin G1 type) fusion protein.

DRUG

Placebo

Placebo contains only excipients.

Trial Locations (1)

Shanghai General Hospita, Shanghai

All Listed Sponsors

lead

Starmab biologics（Shanghai）Co,.ltd

INDUSTRY

NCT06014736 - A Phase I Study of XJ101 in Chinese Healthy Subjects | Biotech Hunter | Biotech Hunter